[Management of glucocorticoid-induced osteoporosis]

Osteoporosis is the most frequent adverse effect observed during glucocorticoids therapy. The 2004 edition of the guideline on the management and treatment of glucocorticoid-induced osteoporosis has been proposed by The Japanese Society for Bone and Mineral Research. The subjects were patients with using or planning to use oral glucocorticoids for 3 months or longer. The criterion for starting treatment consisted patients with prior fragility fracture and with new fractures during treatment, patients with less BMD than %YAM80, and patients with using as a dose of 5 mg/day or higher (mean daily dose) as prednisolone equivalent. The Bisphosphonates have been recommended as first-line drugs. Active vitamin D3 and vitamin K2 have been recommended as second-line drugs.